Atlas company financials

MADRIGAL PHARMACEUTICALS, INC.

Standardized 10-year financial series for MADRIGAL PHARMACEUTICALS, INC., built from filing-derived source data and exposed in JSON, CSV, and XLSX so it can feed iterFact artifacts or analyst workflows without hand-entering the numbers.

United StatesCIK 0001157601FY2012 → FY2025

Open JSON Download CSV Download XLSX Quarterly JSON Summary JSON Filing index

Latest fiscal year

FY2025

Revenue

$958.4M

Adjusted EBITDA

—

Net result

-$288.3M

Net financial debt

$141.2M

Latest source: FY2025 filing · published data snapshot generated April 26, 2026

Phase 2 summary

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

Latest quarter revenue

$287.3M

TTM revenue

$699.5M

TTM free cash flow

—

Latest quarter net result

-$114.2M

Quarterly coverage: 20 periods · latest quarter FY2025-Q3 · TTM revenue growth 4678.6%.

What this gives you

A proof-of-concept company data surface, not a dead PDF shelf.

The same standardized payload behind this page is exposed through downloadable CSV and XLSX files plus a stable JSON route. That makes it usable as a live input to iterFact templates, a spreadsheet handoff, or a future API surface without re-normalizing the source documents again.

Source audit

Official links first, raw iterFact payloads right next to them.

Official sources

SEC EDGAR companyfacts
primary · madrigal-pharmaceuticals-inc-fy2012 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2015-03-12 · Retrieved: 2026-04-26T11:47:07.134847+00:00
SEC EDGAR companyfacts
us-gaap:OperatingIncomeLoss · us gaap companyfacts · primary · madrigal-pharmaceuticals-inc-fy2012 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2013-03-14 · Retrieved: 2026-04-26T11:47:07.134847+00:00
SEC EDGAR companyfacts
primary · madrigal-pharmaceuticals-inc-fy2017 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2020-02-26 · Retrieved: 2026-04-26T11:47:07.134847+00:00
SEC EDGAR companyfacts
us-gaap:OperatingIncomeLoss · us gaap companyfacts · primary · madrigal-pharmaceuticals-inc-fy2017 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2018-03-13 · Retrieved: 2026-04-26T11:47:07.134847+00:00
SEC EDGAR companyfacts
us-gaap:NetIncomeLoss · us gaap companyfacts · comparative · madrigal-pharmaceuticals-inc-fy2017 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2019-02-27 · Retrieved: 2026-04-26T11:47:07.134847+00:00

Ten-year series

Headline company financials by fiscal year

Fiscal year	Revenue	Adj. EBITDA	EBIT	Net result	Op. cash flow	Capex	Net debt	Status
FY2012	147K	—	-61M	—	-54M	-505K	—	missing accounts receivable · missing adjusted ebitda · missing basic eps · missing cost of revenue · missing diluted eps · missing diluted weighted average shares · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing net result · missing research and development · missing sg and a
FY2017	0	—	-32M	-31M	-22M	-125K	—	missing accounts receivable · missing adjusted ebitda · missing basic eps · missing cost of revenue · missing diluted eps · missing diluted weighted average shares · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing research and development · missing sg and a
FY2018	0	—	-41M	-33M	-26M	-22K	—	missing accounts receivable · missing adjusted ebitda · missing basic eps · missing cost of revenue · missing diluted eps · missing diluted weighted average shares · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing research and development · missing sg and a
FY2019	0	—	-95M	-84M	-42M	-172K	—	missing accounts receivable · missing adjusted ebitda · missing basic eps · missing cost of revenue · missing diluted eps · missing diluted weighted average shares · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing research and development · missing sg and a
FY2020	0	—	-207M	-202M	-158M	-334K	—	missing accounts receivable · missing adjusted ebitda · missing cost of revenue · missing gross profit · missing inventory · missing net financial debt · missing research and development · missing sg and a
FY2021

Filing provenance

Every year stays linked back to its source document.

FY2012partial

SEC EDGAR companyfacts · XBRL · consolidated_reported

missing_accounts_receivable · missing_adjusted_ebitda · missing_basic_eps · missing_cost_of_revenue · missing_diluted_eps · missing_diluted_weighted_average_shares · missing_gross_profit · missing_interest_expense · missing_inventory · missing_net_financial_debt · missing_net_result · missing_research_and_development · missing_sg_and_a

Open official source filing

FY2017partial

SEC EDGAR companyfacts · XBRL · consolidated_reported

Open official source filing

FY2018partial

SEC EDGAR companyfacts · XBRL · consolidated_reported

Open official source filing

FY2019partial

SEC EDGAR companyfacts · XBRL · consolidated_reported

Open official source filing

MADRIGAL PHARMACEUTICALS, INC.

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

A proof-of-concept company data surface, not a dead PDF shelf.

Official links first, raw iterFact payloads right next to them.

Official sources

Headline company financials by fiscal year

Every year stays linked back to its source document.

iterFact raw links

Methodology

Data vintage